• Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 386.85%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.05
▼ -0.07 (-3.30%)

This chart shows the closing price for PULM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pulmatrix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PULM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PULM

Analyst Price Target is $10.00
▲ +386.85% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Pulmatrix in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 386.85% upside from the last price of $2.05.

This chart shows the closing price for PULM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Pulmatrix. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
2/7/2023HC WainwrightReiterated RatingBuy$10.00Low
3/30/2022HC WainwrightReiterated RatingBuy$5.00 ➝ $10.00Medium
4/13/2021HC WainwrightLower TargetBuy$200.00 ➝ $100.00High
9/24/2020HC WainwrightReiterated RatingBuy$200.00Medium
11/10/2019HC WainwrightReiterated RatingBuy$200.00Medium
(Data available from 7/16/2019 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/19/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/17/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/18/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/17/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/16/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2024

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Pulmatrix logo
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $2.05
Low: $1.98
High: $2.13

50 Day Range

MA: $1.94
Low: $1.78
High: $2.19

52 Week Range

Now: $2.05
Low: $1.55
High: $2.75

Volume

14,086 shs

Average Volume

10,899 shs

Market Capitalization

$7.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Pulmatrix?

The following equities research analysts have issued reports on Pulmatrix in the last year: HC Wainwright, and StockNews.com.
View the latest analyst ratings for PULM.

What is the current price target for Pulmatrix?

1 Wall Street analysts have set twelve-month price targets for Pulmatrix in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 386.9%. HC Wainwright has the highest price target set, predicting PULM will reach $10.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $10.00 for Pulmatrix in the next year.
View the latest price targets for PULM.

What is the current consensus analyst rating for Pulmatrix?

Pulmatrix currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PULM will outperform the market and that investors should add to their positions of Pulmatrix.
View the latest ratings for PULM.

What other companies compete with Pulmatrix?

How do I contact Pulmatrix's investor relations team?

Pulmatrix's physical mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 357-2333 and its investor relations email address is [email protected]. The official website for Pulmatrix is www.pulmatrix.com. Learn More about contacing Pulmatrix investor relations.